August 22, 2025

Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Pharmacokinetic exposure impacts toxicity and response in patients with acute myeloid leukemia, suggesting tailored treatments.

Steady-state plasma levels of tp-0903 were significantly different between responders and non-responders, indicating varying responses.
Absolute neutrophil count dropped significantly in patients with steady-state plasma levels above the median, highlighting a potential correlation.
Assessment involved pharmacokinetic measures for tp-0903 and decitabine in older patients with acute myeloid leukemia.
These findings may enable more personalized treatment strategies for acute myeloid leukemia in older adults.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark